viewCreso Pharma Ltd

Creso Pharma signs sports distribution deal with ImpACTIVE to drive growth in North America and Europe

Under the agreement, ImpACTIVE will distribute Creso Pharma’s cannaDOL and cannaQIX® products through its established sales channels in Canada and the USA.

Creso Pharma Ltd - Creso Pharma signs letter of intent with ImpACTIVE  to drive growth in North America and Europe
As part of the LOI, Creso will also obtain the rights to distribute ImpACTIVE’s CBD roller application in Switzerland and Europe.

Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has signed a non-binding letter of intent (LOI) with ImpACTIVE Holdings Ltd to distribute the company’s suite of hemp CBD based human health products, CannaDOL and cannaQIX®, in Canada and the US.

ImpACTIVE was founded by current and former high-profile athletes who have struggled with injury and wanted to provide an alternative treatment route to the athletic community and has developed a range of CBD-based products, designed to reduce muscle and joint inflammation without the use of heavy narcotics or prescription pharmaceuticals.

As part of the LOI, Creso will also obtain the rights to distribute ImpACTIVE’s CBD roller application in Switzerland and Europe.

“Large market opportunity”

The global market for CBD products in the sport and recreation industries is estimated to be valued at US$22 billion by 2022 and C$220 million in Canada alone.

Creso commercial director Jorge Wernli said: “We are very proud to enter the sports and recreational market with such a high calibre partner as ImpACTIVE.

“This LOI is important for Creso Pharma, as it further broadens our international footprint and provides another large market opportunity.

“We look forward to working with ImpACTIVE to ensure all products are well received in Europe and North America, and also leveraging their innovative product range to further add to the company’s growing sales profile.”

European distribution plans

The company will also become an authorised distributor of ImpACTIVE’s CBD based roll-on product range, with an initial focus on Switzerland where Creso will target the growing sports and recreational market through a range of retail outlets.

Creso has access to more than 2,100 pharmacies, drug stores and specialised retailers as well as in excess of 400 sport and fitness centres, and large specialist retailer groups, and expects to receive strong uptake.

The launch of the product range is anticipated in April 2021.

Key terms

The initial term of the agreement is one year and will automatically renew after one year unless either party notifies the other of their decision to not renew the agreement within 90 days prior to the expiry of the initial or renewal term.

Each distributing party is responsible for obtaining all the necessary regulatory approvals and registrations required to sell the hemp CBD based products in the relevant jurisdiction.

Quick facts: Creso Pharma Ltd

Price: 0.2 AUD

Market: ASX
Market Cap: $220.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...


Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 12/6/20

2 min read